Hyaluronic acid-green tea catechin conjugates as a potential therapeutic agent for rheumatoid arthritis.
Fan LeeKi Hyun BaeShengyong NgAtsushi YamashitaMotoichi KurisawaPublished in: RSC advances (2021)
Fibroblast-like synoviocytes are a key effector cell type involved in the pathogenesis of rheumatoid arthritis. The major green tea catechin, epigallocatechin-3- O -gallate (EGCG), has attracted significant interest for rheumatoid arthritis therapy because of its ability to suppress the proliferation and interleukin-6 secretion of synoviocytes. However, therapeutic efficacy of EGCG has been limited by a lack of target cell specificity. Herein we report hyaluronic acid-EGCG (HA-EGCG) conjugates as an anti-arthritic agent that is capable of targeting fibroblast-like synoviocytes via HA-CD44 interactions. These conjugates exhibited superior anti-proliferative and anti-inflammatory activities compared with EGCG under simulated physiological conditions. Near-infrared fluorescence imaging revealed preferential accumulation of the conjugates at inflamed joints in a collagen-induced arthritis rat model, and their anti-arthritic efficacy was investigated by measuring a change in the edema and histopathological scores. Our findings suggest the potential of HA-EGCG conjugates as an anti-arthritic agent for the treatment of rheumatoid arthritis.
Keyphrases
- rheumatoid arthritis
- hyaluronic acid
- cancer therapy
- disease activity
- fluorescence imaging
- ankylosing spondylitis
- interstitial lung disease
- anti inflammatory
- single cell
- stem cells
- photodynamic therapy
- wound healing
- dendritic cells
- immune response
- drug induced
- regulatory t cells
- idiopathic pulmonary fibrosis
- mass spectrometry
- tissue engineering